Pharma

Jan 8 2018

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #research #pharma

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Jan 8 2018

Cipla, Aurobindo Pharma acquire products divested by Teva in US #pharmaceutical #manufacturers #association

#aurobindo pharma # Cipla, Aurobindo Pharma acquire products divested by Teva in US On Thursday, the US FTC approved Teva’s purchase of Allergan’s generic drug-making unit. Photo: Reuters Hyderabad: Cipla Ltd, India s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc s generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission (FTC), …

Dec 31 2017

Jazz Pharmaceuticals to acquire Azur Pharma #bio #pharmaceutical #companies

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Dec 19 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #major #pharmaceutical #companies

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Nov 30 2017

Cipla, Aurobindo Pharma acquire products divested by Teva in US #noel #pharma

#aurobindo pharma # Cipla, Aurobindo Pharma acquire products divested by Teva in US On Thursday, the US FTC approved Teva’s purchase of Allergan’s generic drug-making unit. Photo: Reuters Hyderabad: Cipla Ltd, India s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc s generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission (FTC), …

Nov 24 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #sandoz #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Nov 5 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #q #pharma

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

Oct 4 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #leo #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Sep 6 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #research #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Aug 27 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #pharmaceutical #wholesalers

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Aug 15 2017

Cipla, Aurobindo Pharma acquire products divested by Teva in US #online #pharma

#aurobindo pharma # Cipla, Aurobindo Pharma acquire products divested by Teva in US On Thursday, the US FTC approved Teva’s purchase of Allergan’s generic drug-making unit. Photo: Reuters Hyderabad: Cipla Ltd, India s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc s generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission (FTC), …

Aug 14 2017

India s Sun to acquire Dusa Pharma #pharma #pipeline

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Aug 9 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #robinson #pharma

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Aug 2 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #pharma #biotech #jobs

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

Aug 2 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #galapagos #pharma

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Aug 1 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #mds #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Jul 23 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #kemwell #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Jul 22 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #pharma #manufacturer

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Jul 12 2017

Jazz Pharmaceuticals to acquire Azur Pharma #fdc #pharma

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Jul 9 2017

Cipla, Aurobindo Pharma acquire products divested by Teva in US #new #pharmaceutical #companies

#aurobindo pharma # Cipla, Aurobindo Pharma acquire products divested by Teva in US On Thursday, the US FTC approved Teva’s purchase of Allergan’s generic drug-making unit. Photo: Reuters Hyderabad: Cipla Ltd, India s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc s generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission (FTC), …

Jul 8 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #diamond #pharma

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Jul 6 2017

Jazz Pharmaceuticals to acquire Azur Pharma #zosano #pharma

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Jul 5 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #list #pharmaceutical #companies

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

Jun 17 2017

Jazz Pharmaceuticals to acquire Azur Pharma #pharmaceutical #sales #rep

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Jun 14 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #pharma #conference

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

May 16 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #pharma #biotech #jobs

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

May 13 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #astellas #pharma #inc

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Apr 29 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #contract #pharmaceutical #manufacturing

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Apr 28 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #pharma #marketing #research

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Apr 23 2017

Jazz Pharmaceuticals to acquire Azur Pharma #biotechnology

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Apr 20 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #zuellig #pharma

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

Apr 20 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #mds #pharma #services

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Apr 20 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #pharmaceutical #industry #growth

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Apr 14 2017

Jazz Pharmaceuticals to acquire Azur Pharma #qrx #pharma

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Apr 11 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #largest #pharmaceutical #companies

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Apr 11 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #ajanta #pharma

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Apr 10 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #asia #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Apr 9 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #drug #manufacturer

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Apr 2 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #health #it #companies

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Mar 30 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #biopharma

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Mar 15 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #pharma #industries

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Mar 15 2017

India s Sun to acquire Dusa Pharma #pharma #consultants

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Feb 13 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #pharma #index

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …

Feb 12 2017

Forest Laboratories to Acquire Furiex Pharmaceuticals #market #research #reports

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Feb 12 2017

Cipla, Aurobindo Pharma acquire products divested by Teva in US #sciele #pharma

#aurobindo pharma # Cipla, Aurobindo Pharma acquire products divested by Teva in US On Thursday, the US FTC approved Teva’s purchase of Allergan’s generic drug-making unit. Photo: Reuters Hyderabad: Cipla Ltd, India s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc s generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission (FTC), …

Feb 11 2017

India s Sun to acquire Dusa Pharma #map #pharma

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Feb 8 2017

Jazz Pharmaceuticals to acquire Azur Pharma #pharma #agency

#azur pharma # Jazz Pharmaceuticals to acquire Azur Pharma James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court with attorney Ethan Balogh in New York, U.S. on Jan. 4, 2011. Fleishman and two ex-consultants for expert-networking firm Primary Global Research LLC were released on bail after a hearing before a New York federal judge as part of their prosecution in a nationwide probe of hedge fund insider trading. Photographer: Jeremy Bales/Bloomberg *** Local Caption *** James Fleishman; Ethan Balogh James Fleishman, a former sales manager at Primary Global Research LLC, right, leaves federal court …

Feb 1 2017

Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #aspen #pharma

#epic pharma # Related Breaking News Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities. The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of …

Feb 1 2017

Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #pharmaceutical #business #plan

#epic pharma # Humanwell and PuraCap to acquire Epic Pharma for $550m Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m. With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities. The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances. Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products. The …

Feb 1 2017

Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #shionogi #pharma #inc

#epic pharma # Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and …